Drug Trial Radar · NCT03524118
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
Last checked: Nov 20, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Sep 20, 2018
Primary completion
Sep 14, 2022
Study completion Sep 14, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 weeks, up to 8 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and incidence of anti-drug antibodies (ADAs) of single ascending doses of clesrovimab in healthy pre-term (born at 29 to 35 weeks gestational age) and full-term (born at \>35 weeks gestational age) infants. Participants will be randomized into 1 of 4 dose escalation panels (Panels A to D); an additional panel (Panel E) of full-term infants will receive the same dose as Panel D. Key safety and tolerability variables will be reviewed after each dose panel prior to administering the next-highest dose.
Conditions
- Respiratory Tract Infection
- Respiratory Syncytial Virus
Interventions
ClesrovimabDrug
Single ascending doses of clesrovimab will be administered via IM injection.
PlaceboDrug
Placebo (0.9% sodium chloride \[NaCl\]) will be administered via IM injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced At Least One Solicited Injection Site Adverse Event (AE)Time frame: Up to Day 5
- Percentage of Participants Who Experienced At Least One Solicited Systemic Adverse Event (AE)Time frame: Up to Day 5
- Percentage of Participants Who Experienced At Least One Serious Adverse Event (SAE)Time frame: Up to Day 545
Locations
34 sites in 6 countries. Site status is shown where the registry gives one.
Children's Hospital - Colorado ( Site 0067)
Aurora, Colorado
Next Phase Research Alliance, LLC ( Site 0075)
Homestead, Florida
Acevedo Clinical Research Associates ( Site 0025)
Miami, Florida
Kapiolani Medical Center for Women and Children ( Site 0027)
Honolulu, Hawaii
Cotton-O'Neil Clinical Research Center PediatricCare ( Site 0081)
Topeka, Kansas
Children's Mercy Hospital ( Site 0037)
Kansas City, Missouri
Dartmouth-Hitchcock Medical Center ( Site 0032)
Lebanon, New Hampshire
SUNY Upstate Medical University Hospital ( Site 0029)
Syracuse, New York
WakeMed Health and Hospitals ( Site 0033)
Raleigh, North Carolina
Cincinnati Children's Hospital Medical Center ( Site 0031)
Cincinnati, Ohio
Ohio Pediatric Research Association ( Site 0066)
Dayton, Ohio
Coastal Pediatric Research ( Site 0028)
Charleston, South Carolina
Tribe Clinical Research, LLC ( Site 0082)
Greenville, South Carolina
University of Texas Medical Branch at Galveston ( Site 0039)
Galveston, Texas
Tekton Research, Inc. ( Site 0026)
San Antonio, Texas
Multicare Institute For Research And Innovation ( Site 0035)
Tacoma, Washington
University of Wisconsin American Family Children's Hospital ( Site 0068)
Madison, Wisconsin
Centro de Investigacion Clinica Bradford Hill ( Site 0103)
Santiago, Region M. de Santiago, Chile
Hospital La Florida ( Site 0050)
Santiago, Region M. de Santiago, Chile
Facultad Medicina Universidad de Chile ( Site 0104)
Santiago, Region M. de Santiago, Chile
Hospital Padre Hurtado ( Site 0102)
Santiago, Region M. de Santiago, Chile
Fundacion Hospital San Vicente de Paul ( Site 0097)
Medellín, Antioquia, Colombia
Universidad Pontificia Bolivariana - Clinica Universitaria Bolivariana ( Site 0098)
Medellín, Antioquia, Colombia
MedPlus Medicina Prepagada S.A. ( Site 0095)
Bogotá, Bogota D.C., Colombia
Fundacion Universitaria de Ciencias de la Salud - Sociedad de Cirugia ( Site 0099)
Bogotá, Bogota D.C., Colombia
Centro de Atención e Investigación Médica SAS - CAIMED CHIA ( Site 0100)
Chía, Cundinamarca, Colombia
Fundacion Valle del Lili ( Site 0090)
Cali, Valle del Cauca Department, Colombia
Chris Hani Baragwanath Academic Hospital ( Site 0262)
Johannesburg, Gauteng, South Africa
Tygerberg Hospital ( Site 0261)
Cape Town, Western Cape, South Africa
Seoul National University Hospital ( Site 0071)
Seoul, South Korea
Severance Hospital Yonsei University Health System ( Site 0073)
Seoul, South Korea
Samsung Medical Center ( Site 0072)
Seoul, South Korea
Hospital Universitario La Paz ( Site 0242)
Madrid, Spain
Hospital Clinico Universitario de Santiago ( Site 0241)
Santiago de Compostela, La Coruna, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.